Altimmune, Inc. - Common Stock (ALT)

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape.

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement.

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.